Alpha 2.0
Login Register
» Authors » Leslie Lilly

Leslie Lilly

Explore the profile of Leslie Lilly including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 361
Followers 0
Related Specialties
General Surgery
Gastroenterology
Public Health
Top 10 Co-Authors
Nazia Selzner
Mamatha Bhat
Mark Cattral
Anand Ghanekar
Markus Selzner
Cynthia Tsien
Gonzalo Sapisochin
Wei Xu
Elmar Jaeckel
Shiyi Chen
Published In
Liver Transpl
Transplantation
Hepatology
Ann Hepatol
Lancet Digit Health
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-Term Survival of Canadian Liver Transplant Recipients Remains Stagnant- A Cohort Study on the Evolution of Cause-Specific Mortality
Zhao X, Xu C, Bera C, Arisar F, Naghibzadeh M, Azhie A, et al.
Dig Dis Sci . 2024 Dec; 70(2):543-551. PMID: 39681747
Objective: Recent U.S. registry publications showed no improvement in long-term survival post-liver transplant in the last three decades. Cardiovascular disease was a leading cause of post-transplant mortality. This observation urged...
2.
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
Zheng K, Azhie A, You X, Naghibzadeh M, Tan E, Naimimohasses S, et al.
Diabetes Obes Metab . 2024 Jul; 26(10):4261-4272. PMID: 39056216
Aim: To investigate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors in liver transplant (LT) recipients with diabetes. Methods: A single-centre, retrospective analysis...
3.
Should advanced donor age be a deterrent in the utilization of grafts from donation after cardiac death in deceased donor liver transplantation? The Toronto experience
Ray S, Shwaartz C, Sayed B, Sapisochin G, Ghanekar A, McGilvray I, et al.
Can J Surg . 2023 Nov; 66(6):E561-E571. PMID: 38016726
Background: Advanced donor age paired with donation after cardiac death (DCD) increases the risk of transplantation, precluding widespread use of grafts from such donors worldwide. Our aim was to analyze...
4.
Trajectories of patients relisted for liver transplantation
Arisar F, Varghese R, Chen S, Xu W, Selzner M, McGilvray I, et al.
Ann Hepatol . 2023 Oct; 29(1):101168. PMID: 37858675
Introduction And Objectives: Recurrent cirrhosis complicates 10-30% of Liver transplants (LT) and can lead to consideration for re-transplantation. We evaluated the trajectories of relisted versus primary listed patients on the...
5.
Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis
Zhao X, Kotha S, Nayyar D, Ma X, Lilly L, Castel H, et al.
Hepatology . 2023 Sep; 79(3):636-649. PMID: 37732952
Background And Aims: Hepatopulmonary syndrome (HPS) is a common complication of liver disease defined by abnormal oxygenation and intrapulmonary vascular dilatation, treated with liver transplantation. Little is known about changes...
6.
Availability of living donor optimizes timing of liver transplant in high-risk waitlisted cirrhosis patients
Arisar F, Chen S, Chen C, Shaikh N, Karnam R, Xu W, et al.
Aging (Albany NY) . 2023 Sep; 15(17):8594-8612. PMID: 37665673
Liver transplant (LT) candidates have become older and frailer, with growing Non-alcoholic steatohepatitis (NASH) and comorbid disease burden in recent years, predisposing them for poor waitlist outcomes. We aimed to...
7.
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis
Onofrio F, Zheng K, Xu C, Chen S, Xu W, Vyas M, et al.
Hepatol Commun . 2023 Aug; 7(8). PMID: 37534935
Background: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na)...
8.
A deep learning framework for personalised dynamic diagnosis of graft fibrosis after liver transplantation: a retrospective, single Canadian centre, longitudinal study
Azhie A, Sharma D, Sheth P, Qazi-Arisar F, Zaya R, Naghibzadeh M, et al.
Lancet Digit Health . 2023 May; 5(7):e458-e466. PMID: 37210229
Background: Recurrent graft fibrosis after liver transplantation can threaten both graft and patient survival. Therefore, early detection of fibrosis is essential to avoid disease progression and the need for retransplantation....
9.
Impact of living donor liver transplantation on long-term cardiometabolic and graft outcomes in cirrhosis due to nonalcoholic steatohepatitis
Karnam R, Azhie A, Yang C, Rogalsky A, Chen S, Xu W, et al.
Clin Transplant . 2023 May; 37(9):e15008. PMID: 37143204
Background And Aim: Non-alcoholic steatohepatitis (NASH) is a leading indication for liver transplantation (LT). This study aimed to determine whether living donor LT (LDLT) recipients experienced less recurrent NASH, cirrhosis,...
10.
Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator
Karnam R, Punchhi G, Mitsakakis N, Chen S, Saracino G, Lilly L, et al.
Clin Transplant . 2023 Feb; 37(4):e14930. PMID: 36762716
Background: Non-alcoholic Steatohepatitis (NASH) cirrhosis is the second most common indication for liver transplantation (LT) in the US and often is associated with significant co-morbidities. We validated a model and...